The move could prove a game-changer in the quest to provide comprehensive cancer treatment, officials said in an interview with NJBIZ.
Hackensack Meridian co-CEO Bob Garrett said that the joint venture will be a “true 50/50 partnership,” and that the two entities have already chosen an unspecified location in central New Jersey for the first jointly owned cancer center. The partners’ respective boards still must approve the location.
“The region seems to have the most need for a cancer center is the central part of the state,” Garrett said. A spokesperson for HMH said that the new cancer center could be up and running by the end of the year.
The joint venture is the next logical step in the partnership that the two entities formed at the end of 2016 to engage in sharing of information, doctors and best practices, and participate in clinical trials. Developing comprehensive cancer care has become a priority for health care providers in New Jersey in the past five years.
Garrett said that HMH and MSK are in the process of developing common clinical care standards that will be applied to the treatment of cancer patients at all of the 11 locations in New Jersey in which HMH treats cancer and all three of MSK’s cancer treatment facilities in New York City and New Jersey.